Indeed, compared to free ALK-siRNA, TL[ALK-siRNA] formulations have low plasma clearance, increased siRNA stability, improved binding to NB cells, and are effective for ALK-silencing and induction of NB cell death [22]. The gene discussed is ALK; the disease is neuroblastoma.